Curative effects of phosphodiesterase 4 inhibitors cilomilast, roflumilast, and rolipram in dermatitis mouse model

Journal of Dermatological Science

Volumn 51, Issue 3, 2008, Pages 215-219

  Harada, Daisuke ^a   Ikeda, Yoshimi ^a   Nosaka, Yukino ^a   Kobayashi, Katsuya ^a   Manabe, Haruhiko ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CILOMILAST; CYCLOSPORIN A; ROFLUMILAST; ROLIPRAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; DERMATITIS; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; DRY SKIN; ERYTHEMA; LETTER; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SKIN DEFECT;

AMINOPYRIDINES; ANIMALS; BENZAMIDES; CARBOXYLIC ACIDS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYCLOPROPANES; DERMATITIS; DERMATITIS, CONTACT; DISEASE MODELS, ANIMAL; EOSINOPHIL PEROXIDASE; INTERLEUKIN-4; MALE; MICE; MICE, INBRED BALB C; NITRILES; PEROXIDASE; PHOSPHODIESTERASE INHIBITORS; PICRYL CHLORIDE; ROLIPRAM;

EID: 48049096585     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2008.04.007     Document Type: Letter

References (10)

1. Lipworth B.J. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365 (2005) 167-175
2. Butler J.M., Chan S.C., Stevens S., and Hanifin J.M. Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis. J Allergy Clin Immunol 71 (1983) 490-497
3. Grewe S.R., Chan S.C., and Hanifin J.M. Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness. J Allergy Clin Immunol 70 (1982) 452-457
4. Hanifin J.M., and Chan S.C. Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis. J Invest Dermatol 105 (1995) 84S-88S
5. Harada D., Tsukumo Y., Takashima Y., and Manabe H. Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application. Eur J Pharmacol 532 (2006) 128-137
6. Akdis C.A., Akdis M., Bieber T., Bindslev-Jensen C., Boguniewicz M., Eigenmann P., et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 118 (2006) 152-169
7. Hanifin J.M., Chan S.C., Cheng J.B., Tofte S.J., Henderson W.R., Kirby D.S., et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 107 (1996) 51-56
8. Kitagaki H., Ono N., Hayakawa K., Kitazawa T., Watanabe K., and Shiohara T. Repeated elicitation of contact hypersensitivity induces a shift in cutaneous cytokine milieu from a T helper cell type 1 to a T helper cell type 2 profile. J Immunol 159 (1997) 2484-2491
9. Barnette M.S. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD). Prog Drug Res 53 (1999) 193-229
10. Matsuda H., Watanabe N., Geba G.P., Sperl J., Tsudzuki M., Hiroi J., et al. Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol 9 (1997) 461-466